Business
EUDA Accelerates Longevity Strategy with Launch of Comprehensive Stem Cell Therapy Platform and First Clinic in Shenzhen
SINGAPORE, Dec. 23, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced a significant acceleration of its longevity and regenerative medicine strategy with the launch of a comprehensive stem cell therapy platform and establishment of its first clinic in Shenzhen, China. This strategic advancement builds on the Company’s earlier acquisitio
About this update from Euda Health Holdings Limited
[{"type":"text","content":"SINGAPORE, Dec. 23, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced a significant acceleration of its longevity and regenerative medicine strategy with the launch of a comprehensive stem cell therapy platform and establishment of its first clinic in Shenzhen, China.","length":430,"tagName":"p"},{"type":"text","content":"This strategic advancement builds on the Company’s earlier acquisition of distribution rights for T-cell immunotherapies developed by Shenzhen Inno Immune Co. Ltd. (“Shenzhen Inno”), a developer of autologous cellular therapeutic and customized medicines for a wide range of diseases in China, and its announced intention to acquire GO POSB Organoids Pte Ltd. (“GO POSB”), a biotechnology company formed in Singapore.","length":417,"tagName":"p"},{"type":"text","content":"Integrated Production and Innovation Center","length":43,"tagName":"p"},{"type":"text","content":"EUDA is upgrading Shenzhen Inno’s cGMP facility in Shenzhen to create a state-of-the-art production and innovation center for stem cell treatments. This advancement incorporates GO POSB’s proprietary induced pluripotent stem cell (“iPSC”) technological platform with advanced stem cell technologies sourced from two Japanese partners, including Japan Early Light Medical Corporation. The enhanced cGMP facility will be essential for supporting iPSC expansion, stem cell preparation, immune cell therapies, and the development of new treatments focused on immune health, skin health, and healthy aging. The Company and its partners will also explore cell-based solutions using iPSC technology, which converts human blood cells into stem cells capable of becoming nearly any cell type.","length":783,"tagName":"p"},{"type":"text","content":"Establishment of Shenzhen Longevity Clinic ","length":42,"tagName":"p"},{"type":"text","content":"In parallel with the upgrade of Shenzhen Inno’s cGMP facility, EUDA, in partnership with KB International Ltd., established a new longevity clinic in Shenzhen. This clinic is strategically positioned to be the first in the region to comprehensively introduce Japanese longevity healthcare technologies. It will offer a differentiated portfolio of services, including:","length...